title: Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.
abstract: There is growing evidence that metabolic alterations play an important role in cancer development and progression. The metabolism of cancer cells is reprogrammed in order to support their rapid proliferation. Elevated fatty acid synthesis is one of the most important aberrations of cancer cell metabolism. An enhancement of fatty acids synthesis is required both for carcinogenesis and cancer cell survival, as inhibition of key lipogenic enzymes slows down the growth of tumor cells and impairs their survival. Based on the data that serum fatty acid synthase (FASN), also known as oncoantigen 519, is elevated in patients with certain types of cancer, its serum level was proposed as a marker of neoplasia. This review aims to demonstrate the changes in lipid metabolism and other metabolic processes associated with lipid metabolism in pancreatic ductal adenocarcinoma (PDAC), the most common pancreatic neoplasm, characterized by high mortality. We also addressed the influence of some oncogenic factors and tumor suppressors on pancreatic cancer cell metabolism. Additionally the review discusses the potential role of elevated lipid synthesis in diagnosis and treatment of pancreatic cancer. In particular, FASN is a viable candidate for indicator of pathologic state, marker of neoplasia, as well as, pharmacological treatment target in pancreatic cancer. Recent research showed that, in addition to lipogenesis, certain cancer cells can use fatty acids from circulation, derived from diet (chylomicrons), synthesized in liver, or released from adipose tissue for their growth. Thus, the interactions between de novo lipogenesis and uptake of fatty acids from circulation by PDAC cells require further investigation.
authors.affiliation: Julian Swierczynski, Areta Hebanowska, Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
authors.forename: Julian
authors.initials: J
authors.lastname: Swierczynski
authors.affiliation: Julian Swierczynski, Areta Hebanowska, Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
authors.forename: Areta
authors.initials: A
authors.lastname: Hebanowska
authors.affiliation: Julian Swierczynski, Areta Hebanowska, Department of Biochemistry, Medical University of Gdansk, 80-211 Gdansk, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Sledzinski
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D021441:Carcinoma, Pancreatic Ductal / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D018450:Disease Progression; D004734:Energy Metabolism / Q000187:drug effects; D054890:Fatty Acid Synthase, Type I / Q000378:metabolism; D005227:Fatty Acids / Q000378:metabolism; D006801:Humans; D050155:Lipogenesis / Q000187:drug effects; D010190:Pancreatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D011237:Predictive Value of Tests; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D005227:Fatty Acids; C518729:FASN protein, human; D054890:Fatty Acid Synthase, Type I
keywords: Cyclooxygenase-2; Farnesylation; Fatty acid synthase; Hypoxia inducible factor 1α; Lipid metabolism; Lipogenic enzymes inhibitors; Monounsaturated fatty acids; Oncogenes; Pancreatic cancer; Tumor suppressors